- Home
- FBRT vs AUPH Comparison
FBRT vs AUPH Comparison
Compare FBRT & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBRT
- AUPH
- Stock Information
- Founded
- FBRT 2012
- AUPH 1993
- Country
- FBRT United States
- AUPH Canada
- Employees
- FBRT N/A
- AUPH N/A
- Industry
- FBRT Real Estate Investment Trusts
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- FBRT Real Estate
- AUPH Health Care
- Exchange
- FBRT Nasdaq
- AUPH Nasdaq
- Market Cap
- FBRT 933.1M
- AUPH 999.8M
- IPO Year
- FBRT 1985
- AUPH 1999
- Fundamental
- Price
- FBRT $11.56
- AUPH $7.82
- Analyst Decision
- FBRT Strong Buy
- AUPH Strong Buy
- Analyst Count
- FBRT 6
- AUPH 2
- Target Price
- FBRT $15.25
- AUPH $11.50
- AVG Volume (30 Days)
- FBRT 450.6K
- AUPH 1.1M
- Earning Date
- FBRT 04-28-2025
- AUPH 05-12-2025
- Dividend Yield
- FBRT 12.23%
- AUPH N/A
- EPS Growth
- FBRT N/A
- AUPH N/A
- EPS
- FBRT 0.67
- AUPH 0.27
- Revenue
- FBRT $175,693,000.00
- AUPH $247,295,000.00
- Revenue This Year
- FBRT $24.81
- AUPH $11.86
- Revenue Next Year
- FBRT $4.20
- AUPH $24.96
- P/E Ratio
- FBRT $17.33
- AUPH $29.34
- Revenue Growth
- FBRT N/A
- AUPH 29.20
- 52 Week Low
- FBRT $10.50
- AUPH $4.98
- 52 Week High
- FBRT $14.12
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- FBRT 49.62
- AUPH 43.65
- Support Level
- FBRT $11.06
- AUPH $7.89
- Resistance Level
- FBRT $11.54
- AUPH $8.38
- Average True Range (ATR)
- FBRT 0.25
- AUPH 0.28
- MACD
- FBRT 0.07
- AUPH -0.01
- Stochastic Oscillator
- FBRT 81.72
- AUPH 2.90
About FBRT Franklin BSP Realty Trust Inc.
Franklin BSP Realty Trust Inc is a private real estate investment trust that originates, acquires, and manages a diversified portfolio of commercial real estate debt, and first mortgage loans. secured by properties located in the United States. Its segments include the real estate debt business; the real estate securities business; the real estate owned business; and the commercial real estate conduit business.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.